174 related articles for article (PubMed ID: 18037786)
1. Production of cross-reactive peptide antibodies against viral capsid proteins of human enterovirus B to apply diagnostic reagent.
Jeong SY; Ahn J; Cho YJ; Kim YJ; Kim DS; Jee Y; Lee H; Nam JH
Microbiol Immunol; 2007; 51(11):1091-8. PubMed ID: 18037786
[TBL] [Abstract][Full Text] [Related]
2. Development of a enterovirus diagnostic assay system for diagnosis of viral myocarditis in humans.
Lim BK; Ju ES; Lao DH; Yun SH; Lee YJ; Kim DK; Jeon ES
Microbiol Immunol; 2013 Apr; 57(4):281-7. PubMed ID: 23586632
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge.
Kim JY; Jeon ES; Lim BK; Kim SM; Chung SK; Kim JM; Park SI; Jo I; Nam JH
Vaccine; 2005 Feb; 23(14):1672-9. PubMed ID: 15705471
[TBL] [Abstract][Full Text] [Related]
4. VP2 dominated CD4+ T cell responses against enterovirus 71 and cross-reactivity against coxsackievirus A16 and polioviruses in a healthy population.
Tan S; Tan X; Sun X; Lu G; Chen CC; Yan J; Liu J; Xu W; Gao GF
J Immunol; 2013 Aug; 191(4):1637-47. PubMed ID: 23863902
[TBL] [Abstract][Full Text] [Related]
5. Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein.
Kiener TK; Jia Q; Lim XF; He F; Meng T; Chow VT; Kwang J
Virol J; 2012 Feb; 9():55. PubMed ID: 22361222
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
[TBL] [Abstract][Full Text] [Related]
7. Viral protein VP4 is a target of human antibodies enhancing coxsackievirus B4- and B3-induced synthesis of alpha interferon.
Chehadeh W; Lobert PE; Sauter P; Goffard A; Lucas B; Weill J; Vantyghem MC; Alm G; Pigny P; Hober D
J Virol; 2005 Nov; 79(22):13882-91. PubMed ID: 16254324
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a panel of in-house polyclonal antibodies for the diagnosis of enterovirus infections.
Kotani O; Iwata-Yoshikawa N; Suzuki T; Sato Y; Nakajima N; Koike S; Iwasaki T; Sata T; Yamashita T; Minagawa H; Taguchi F; Hasegawa H; Shimizu H; Nagata N
Neuropathology; 2015 Apr; 35(2):107-21. PubMed ID: 25263613
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of enterovirus 70 capsid protein VP1 and its non-overlapping N- and C-terminal fragments.
Chen D; Duggan C; Texada DE; Reden TB; Kooragayala LM; Langford MP
Antiviral Res; 2005 Jun; 66(2-3):111-7. PubMed ID: 15911028
[TBL] [Abstract][Full Text] [Related]
10. Expression of an antigenic adenovirus epitope in a group B coxsackievirus.
Höfling K; Tracy S; Chapman N; Kim KS; Smith Leser J
J Virol; 2000 May; 74(10):4570-8. PubMed ID: 10775593
[TBL] [Abstract][Full Text] [Related]
11. An Albumin-Binding Domain Peptide Confers Enhanced Immunoprotection Against Viral Myocarditis by CVB3 VP1 Vaccine.
Gao Y; Yue Y; Xiong S
Front Immunol; 2021; 12():666594. PubMed ID: 34630378
[No Abstract] [Full Text] [Related]
12. Enterovirus infection may induce humoral immune response reacting with islet cell autoantigens in humans.
Härkönen T; Paananen A; Lankinen H; Hovi T; Vaarala O; Roivainen M
J Med Virol; 2003 Mar; 69(3):426-40. PubMed ID: 12526055
[TBL] [Abstract][Full Text] [Related]
13. Induction of neutralizing antibodies by the coxsackievirus B3 virion polypeptide, VP2.
Beatrice ST; Katze MG; Zajac BA; Crowell RL
Virology; 1980 Jul; 104(2):426-38. PubMed ID: 6249036
[No Abstract] [Full Text] [Related]
14. Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination.
Lan J; Gao Z; Xiong H; Chuai X; Jin Y; Li J; Xian X; Liu G; Xie L; Zhang Y; Wang Y
Vaccine; 2011 Sep; 29(40):6894-902. PubMed ID: 21803097
[TBL] [Abstract][Full Text] [Related]
15. Expression of capsid [correction of caspid] protein VP1 for use as antigen for the diagnosis of enterovirus 71 infection.
Shih SR; Li YS; Chiou CC; Suen PC; Lin TY; Chang LY; Huang YC; Tsao KC; Ning HC; Wu TZ; Chan EC
J Med Virol; 2000 Jun; 61(2):228-34. PubMed ID: 10797379
[TBL] [Abstract][Full Text] [Related]
16. Incomplete immune response to coxsackie B viruses associates with early autoimmunity against insulin.
Ashton MP; Eugster A; Walther D; Daehling N; Riethausen S; Kuehn D; Klingel K; Beyerlein A; Zillmer S; Ziegler AG; Bonifacio E
Sci Rep; 2016 Sep; 6():32899. PubMed ID: 27604323
[TBL] [Abstract][Full Text] [Related]
17. AIM2 Co-immunization with VP1 Is Associated with Increased Memory CD8 T Cells and Mounts Long Lasting Protection against Coxsackievirus B3 Challenge.
Yin L; Chai D; Yue Y; Dong C; Xiong S
Front Cell Infect Microbiol; 2017; 7():247. PubMed ID: 28642849
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis.
Zhang L; Parham NJ; Zhang F; Aasa-Chapman M; Gould EA; Zhang H
Vaccine; 2012 Mar; 30(13):2301-8. PubMed ID: 22306858
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis for serological cross-reactivity between enteroviruses.
Samuelson A; Forsgren M; Johansson B; Wahren B; Sällberg M
Clin Diagn Lab Immunol; 1994 May; 1(3):336-41. PubMed ID: 7496972
[TBL] [Abstract][Full Text] [Related]
20. Attenuating mutations in coxsackievirus B3 map to a conformational epitope that comprises the puff region of VP2 and the knob of VP3.
Stadnick E; Dan M; Sadeghi A; Chantler JK
J Virol; 2004 Dec; 78(24):13987-4002. PubMed ID: 15564506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
